ArticleDermatology and therapy2014
Ingenol mebutate: a succinct review of a succinct therapy.
Article in Dermatology and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Latency Reversing Agents and the Road to an HIV CurePathogens (Basel, Switzerland) · 2025Review
- Ingenol mebutate in cancer therapy: mechanisms, clinical applications and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Finding activity through rigidity: syntheses of natural products containing tricyclic bridgehead carbon centers.Natural product reports · 2023Review
- Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives.Clinical, cosmetic and investigational dermatology · 2023Review
- Systematic characterization of metabolic profiles of ingenol in rats by UPLC-Q/TOF-MS and NMR in combination with microbial biotransformation.RSC advances · 2021Article
- Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles.ACS pharmacology & translational science · 2020Article
- Bioactive diterpenoid metabolism and cytotoxic activities of genetically transformed Euphorbia lathyris roots.Phytochemistry · 2020Article
- Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes.Frontiers in pharmacology · 2020Review
- Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis.Scientific reports · 2019Article
- Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.Antimicrobial agents and chemotherapy · 2018Article
- Novel Latency Reversal Agents for HIV-1 Cure.Annual review of medicine · 2018Review
- Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.Therapeutics and clinical risk management · 2018Review
- Patient satisfaction and reported outcomes on the management of actinic keratosis.Clinical, cosmetic and investigational dermatology · 2017Review
- Tattoo removal with ingenol mebutate.Clinical, cosmetic and investigational dermatology · 2017Article
- Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.Retrovirology · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIngenol mebutate is a newly approved topical field therapy for actinic keratosis (AK). It has a dual mechanism of action comprising of a rapid induction of necrosis that specifically targets dysplastic cells, as well as neutrophil-mediated immunostimulatory effects. Such a dual mechanism allows for this agent to clear AK lesions in as little as two to three daily applications, thus providing for improved treatment outcomes and patient satisfaction. REVIEW: Given that this is a new dermatologic therapy, this review summarizes the key literature surrounding this agent. This review covers the indications for use, mechanisms of action, method of administration, efficacy and safety profile and important drug interactions of ingenol mebutate.
conclusionsIngenol mebutate should be considered a highly relevant field therapy for AK and the prevention of progression to squamous cell carcinoma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.